TY - JOUR
T1 - Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
AU - Chow, Timothy G.
AU - Franzblau, Lauren E.
AU - Khan, David A.
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/12
Y1 - 2022/12
N2 - Purpose of Review: The use of biologic therapies has risen exponentially over recent years, allowing for unprecedented disease control within numerous areas of Allergy/Immunology. With this expanded use, awareness and understanding of adverse reactions to biologic agents have also increased. Recent Findings: Multiple biologic adverse reaction phenotypes have been described, but significant overlap in clinical features across phenotypes exists. Given considerable phenotypic overlap, a targeted testing approach may not always be clear, and more recent classifications focus on management decision making using tools of diagnostic challenges and rapid drug desensitizations, guiding clinicians in developing a management plan when the exact underlying mechanism is not clearly known. With increased clinical experience with omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, rituximab, and TNF-inhibitors, there is a growing appreciation to the spectrum and particularities of adverse reactions to these agents which are outlined in this review. Summary: Our understanding of the clinical presentation and management of adverse reactions to biologic medications encountered in Allergy/Immunology has grown. Opportunities remain to further define optimal diagnostic and management strategies for these reactions.
AB - Purpose of Review: The use of biologic therapies has risen exponentially over recent years, allowing for unprecedented disease control within numerous areas of Allergy/Immunology. With this expanded use, awareness and understanding of adverse reactions to biologic agents have also increased. Recent Findings: Multiple biologic adverse reaction phenotypes have been described, but significant overlap in clinical features across phenotypes exists. Given considerable phenotypic overlap, a targeted testing approach may not always be clear, and more recent classifications focus on management decision making using tools of diagnostic challenges and rapid drug desensitizations, guiding clinicians in developing a management plan when the exact underlying mechanism is not clearly known. With increased clinical experience with omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, rituximab, and TNF-inhibitors, there is a growing appreciation to the spectrum and particularities of adverse reactions to these agents which are outlined in this review. Summary: Our understanding of the clinical presentation and management of adverse reactions to biologic medications encountered in Allergy/Immunology has grown. Opportunities remain to further define optimal diagnostic and management strategies for these reactions.
KW - Adverse reaction
KW - Biologic
KW - Desensitization
KW - Hypersensitivity
KW - Omalizumab
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=85141048923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141048923&partnerID=8YFLogxK
U2 - 10.1007/s11882-022-01048-9
DO - 10.1007/s11882-022-01048-9
M3 - Review article
C2 - 36306059
AN - SCOPUS:85141048923
SN - 1529-7322
VL - 22
SP - 195
EP - 207
JO - Current Allergy and Asthma Reports
JF - Current Allergy and Asthma Reports
IS - 12
ER -